ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Hepatitis B Virus Antisense Oligonucleotide AHB-137

Also written as “AHB-137”, “AHB-137 injection” and “AHB-137 (24 weeks)”.

Its studies are mostly in Hepatitis B, Chronic, led by 2 companies.

Drug pageHepatitis B Virus Antisense Oligonucleotide AHB-137: every studyAll 11 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Aug 12, 202511 company-led studies, 8 open or runningNext primary completion: Dec 12, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ausper Biopharma86 open or runningphase 3since Aug 12, 2025Oct 11, 2023Dec 12, 2026phase 2 · NCT07137910
AusperBio Therapeuticsits history only32 open or runningphase 2since Jan 19, 2026Jan 20, 2023May 11, 2027phase 2 · NCT07654283

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Ausper Biopharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 11, 2023First study: phase 2 study in Hepatitis B, ChronicFirst studyNCT06115993 · 129 enrolled · China
  2. Aug 5, 2024Phase 2 study in Hepatitis B, ChronicNCT06550128 · 86 enrolled · China
  3. May 16, 2025Phase 2 study in Hepatitis B, ChronicNCT06993480 · 20 enrolled · China
  4. Jun 25, 2025Phase 2 study in Hepatitis B, ChronicNCT07069569 · 200 planned · China
  5. Aug 12, 2025Phase 3 study in Hepatitis B, ChronicNCT07246889 · 577 enrolled · China
  6. Aug 15, 2025Phase 2 study in Hepatitis B, ChronicNCT07137910 · 200 planned · China
  7. May 14, 2026Phase 1 study in Hepatitis B, ChronicNCT07600788 · 32 planned · China
  8. May 28, 2026Phase 2 study in Hepatitis B, ChronicNCT07635186 · 320 planned · China

Ahead

  1. Dec 12, 2026Primary completion: phase 2 study in Hepatitis B, ChronicNCT07137910
  2. Dec 18, 2026Primary completion: phase 3 study in Hepatitis B, ChronicNCT07246889
  3. Jun 20, 2027Primary completion: phase 2 study in Hepatitis B, ChronicNCT07635186
  4. Jul 15, 2027Primary completion: phase 2 study in Hepatitis B, ChronicNCT07069569

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 8 Ausper Biopharma leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07635186Hepatitis B, Chronic · China2RecruitingJun 20, 2027320
NCT07600788Hepatitis B, Chronic · China1RecruitingMay 15, 202832
NCT07137910Hepatitis B, Chronic · China2RecruitingDec 12, 2026200
NCT07246889Hepatitis B, Chronic · China3Active, not recruitingDec 18, 2026577
NCT07069569Hepatitis B, Chronic · China2RecruitingJul 15, 2027200
NCT06993480Hepatitis B, Chronic · China2Active, not recruitingJul 27, 202720
NCT06550128Hepatitis B, Chronic · China2CompletedMay 26, 202586
NCT06115993Hepatitis B, Chronic · China2CompletedDec 3, 2024129

How it is read

Names in the registry

  • “AHB-137”, 7 entries
  • “AHB-137 injection”, 3 entries
  • “AHB-137 (24 weeks)”, 1 entry
  • “AHB-137 (16 weeks)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.